The fine-tuning of anti-oxidized low-density lipoprotein antibodies in cardiovascular disease and thrombosis

Jozélio Freire de Carvalho; Yaniv Sherer; Yehuda Shoenfeld

doi:10.1160/TH07-11-0652

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 98(06): 1157-1159
DOI: 10.1160/TH07-11-0652

Review Article

Schattauer GmbH

The fine-tuning of anti-oxidized low-density lipoprotein antibodies in cardiovascular disease and thrombosis

Authors

Jozélio Freire de Carvalho

¹Rheumatology Division, São Paulo University School of Medicine, São Paulo, Brazil

²Department of Medicine and, Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Tel-Aviv University Sackler Faculty of Medicine, Israel
Yaniv Sherer

²Department of Medicine and, Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Tel-Aviv University Sackler Faculty of Medicine, Israel
Yehuda Shoenfeld

²Department of Medicine and, Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Tel-Aviv University Sackler Faculty of Medicine, Israel

³Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Tel-Aviv University, Tel-Aviv, Israel

Abstract

Summary

Anti-oxidised low-density lipoprotein (anti-oxLDL) antibodies are a heterogeneous group of autoantibodies including both pathogenic and protective subsets. Whereas in most studies the levels of anti-oxLDL antibodies were associated with enhanced atherosclerosis as evaluated by different methods, immunization with oxLDL leads to elevated levels of anti-oxLDL and protection against atherosclerosis. Anti-oxLDL can also be used for immunomodulation of atherosclerosis (i.e. possible therapeutic use of intravenous immunoglobulin, oral tolerance). More specific autoantibodies out of total anti-oxLDL should be selected, for instance, anti-oxLDL/beta-2-glycoprotein I complex, hence defining the fine-tuning of anti-oxLDL antibodies might detect which autoantibodies are pathogenic and which can be used therapeutically.

Keywords

oxLDL - anti-oxLDL - autoantibodies - cardiovascular diseases - lipoproteins

Full Text

References

References
1 Libby P, Hansson GK. Involvement of the immune system in human atherogeneis: current knowledge and unanswered questions.. Lab Invest 1991; 64: 5-11.
2 Ross R. Atherosclerosis – an inflammatory condition.. N Engl J Med 1999; 340: 115-126.
3 Wick G, Schett G, Amberger A. et al. Is atherosclerosis an immunologically mediated disease?. Immunol Today 1995; 16: 27-33.
4 Steinberg D, Parthasarathy S, Carew TE. et al. Beyond cholesterol: modification of low-density lipoprotein that increase its atherogenicity.. N Engl J Med 1989; 320: 915-924.
5 Witzum JL. The oxidation hypothesis of atherosclerosis.. Lancet 1994; 344: 793-795.
6 Shoenfeld Y, Wu R, Dearing LD. et al. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective: Editorial.. Circulation 2004; 110: 2552-2558.
7 Matsuura E, Kobayashi K, Inoue K. et al. Oxidized LDL/beta-2-glycoprotein I complexes: new aspects in atherosclerosis.. Lupus 2005; 14: 736-741.
8 Bergmark C, Wu R, de Faire U. et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL.. Arterioscler Thromb Vasc Biol 1995; 15: 441-445.
9 Maggi E, Chiesa R, Melissano G. et al. LDL oxidation in patients with severe carotid atherosclerosis: a study in vitro and in vivo oxidation markers.. Arterioscler Thromb Vasc Biol 1994; 14: 1892-1899.
10 Lehtimaki T, Lehtinen S, Solakivi T. et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease.. Arterioscler Thromb Vasc Biol 1999; 19: 23-27.
11 Salonen JT, Yla-Herttuala S, Yamamoto R. et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis.. Lancet 1992; 11: 883-887.
12 Wu R, Nityanand S, Berglund L. et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old-men predict myocardial infarction.. Arterioscler Thromb Vasc Biol 1997; 17: 3159-3163.
13 Puurunen M, Manttari M, Manninen V. et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction.. Arch Intern Med 1994; 154: 2605-2609.
14 Ben-Yehuda O, Witztum JL, Keaney JF. et al. Autoantibody titer to malondialdehyde modified low density lipoprotein correlates with extent of coronary artery disease.. Circulation 1996; 94 (Suppl. 01) 1-638.
15 Fang JC, Kinlay S, Beherndt D. et al. Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation.. Arterioscler Thromb Vasc Biol 2002; 22: 2044-2048.
16 Monaco C, Crea F, Niccoli G. et al. Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease: pathophysiological implications.. Eur Heart J 2001; 22: 1572-1577.
17 Dotevall A, Hulthe J, Rosengre A. et al. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci (Lond.. ) 2001; 101: 523-531.
18 Sherer Y, Tenenbaum A, Praprotnik S. et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein- I, and oxidized LDL antibodies.. Cardiology 2001; 95: 20-24.
19 Raitakari OT, Pitkanen OP, Lehtimaki T. et al. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men.. J Am Coll Cardiol 1997; 30: 97-102.
20 Soltesz P, Veres K, Laczik R. et al. Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syn- drome and stable coronary artery disease.. Thromb Haemost 2007; 98: 413-419.
21 Matsumoto N, Nomura S, Kamihata H. et al. Increased level of oxidized LDL-dependent monocytederived microparticles in acute coronary syndrome.. Thromb Haemost 2004; 91: 146-154.
22 George J, Afek A, Gilburd B. et al. Hyperimmunization of apoE deficient mice with homologous MDAlow density lipoprotein suppresses early atherogenesis.. Atherosclerosis 1998; 138: 147-152.
23 Palinski W, Miller E, Witzum JL. Immunization of low density lipoprotein (LDL) deficient rabbits with homologous malondialdehyde-modified LDL reduces atheroge4nesis.. Proc Natl Acad Sci USA 1995; 92: 821-825.
24 Ameli SA, Hultgardh-Nilsson A, Regnstrom J. et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits.. Arterioscler Thromb Vasc Biol 1996; 16: 1074-1079.
25 Nilsson J, Calara F, Regnstrom J. et al. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon angioplasty in hypercholesterolemic rabbits.. J Am Coll Cardiol 1997; 30: 1886-1891.
26 Weiner H, Freidman A, Miller A. Oral tolerance: immunologic mechanisms and treatment of animal and human organ specific autoimmune diseases by oral administration of autoantigens.. Annu Rev Immunol 1994; 12: 809-837.
27 George J, Yacov N, Breitbart E. et al. Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta-2-glycoprotein I.. Cardiovasc Res 2004; 62: 603-609.
28 Harats D, Yacov N, Gilburd B. et al. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis -induced and high-fat-diet-driven atherosclerotic lesions.. J Am Coll Cardiol 2002; 40: 1333-1338.
29 van Puijvelde GH, Hauer AD, de Vos P. et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis.. Circulation 2006; 114: 1968-1976.
30 Goronzy JJ, Weyand CM. Immunosuppression in atherosclerosis: mobilizing the opposition within.. Circulation 2006; 114: 1901-1904.
31 Nicoletti A, Kaveri S, Caligiuri G. et al. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.. J Clin Invest 1998; 102: 910-918.
32 Wu R, Shoenfeld Y, Sherer Y. et al. Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations – possible immunomodulation of atherosclerosis.. Autoimmunity 2003; 36: 91-97.